The European Medicines Agency has issued guidance explaining how good clinical practice (GCP) inspections requested by its human drugs evaluation committee, the CHMP, will be conducted remotely on a case-by-case basis during the COVID-19 pandemic.
The EMA believes GCP inspections are “indispensable” and should, for the present time, focus on the processes and operations of...